Literature DB >> 7673726

Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.

M Giovarelli1, P Musiani, A Modesti, P Dellabona, G Casorati, A Allione, M Consalvo, F Cavallo, F di Pierro, C De Giovanni.   

Abstract

The cDNA coding for mouse IL-10 (mIL-10) was transduced into the parental cells of a spontaneous adenocarcinoma of BALB/c mice (TSA-pc), and clones secreting small, medium, and large quantities of IL-10 were selected. In vivo, both low and high producer clones do not display an enhanced ability to grow in H-2 and non-H-2 incompatible mice. Instead, the intensity of their rejection increases in function of the amount of mIL-10 released. After an initial growth period in syngeneic mice, high producer clones undergo complete rejection due to the combined action of CD8+ lymphocytes, NK cells, and neutrophils. After this rejection, mice are immune to a subsequent challenge with TSA-pc. This memory rests on a strong lytic activity of CD8+ CTL and granulocytes. Following the rejection, mice also develop anti-TSA Ab that guide the granulocytes in TSA-pc memory reaction. A direct comparison shows that although TSA clones engineered to release IL-2 activate CTL and no anti-TSA Ab, those engineered to release IL-4 activate a strong Ab response but not CTL. The kind of cytokine released by the tumors appears to determine the type of response. However, IL-10 high producer cells do not deviate the immune memory, neither toward a Th1 nor a Th2. Both the CTL activity and the Ab responses induced by IL-10 high producer cells are the strongest so far observed in the TSA system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673726

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 2.  Cytokines that target immune killer cells against tumors.

Authors:  Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2020-06-10       Impact factor: 11.530

3.  IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells.

Authors:  Zhaojun Sun; Julien Fourcade; Ornella Pagliano; Joe-Marc Chauvin; Cindy Sander; John M Kirkwood; Hassane M Zarour
Journal:  Cancer Res       Date:  2015-02-26       Impact factor: 12.701

Review 4.  Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Authors:  F Salazar-Onfray
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 5.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

6.  IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses.

Authors:  Z Xing; J Gauldie; G Cox; H Baumann; M Jordana; X F Lei; M K Achong
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

Review 7.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

Review 8.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

9.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

10.  FOXP3 regulates sensitivity of cancer cells to irradiation by transcriptional repression of BRCA1.

Authors:  Weiquan Li; Hiroto Katoh; Lizhong Wang; Xiaochun Yu; Zhanwen Du; Xiaoli Yan; Pan Zheng; Yang Liu
Journal:  Cancer Res       Date:  2013-01-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.